X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (381) 381
Publication (51) 51
Newsletter (30) 30
Book Review (9) 9
Book Chapter (4) 4
Book / eBook (3) 3
Conference Proceeding (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (293) 293
male (269) 269
index medicus (206) 206
animals (176) 176
prostate cancer (165) 165
glutamate carboxypeptidase ii - metabolism (125) 125
antigens, surface - metabolism (102) 102
glutamate (90) 90
mice (87) 87
expression (82) 82
cancer (74) 74
cell line, tumor (72) 72
glutamate carboxypeptidase ii - antagonists & inhibitors (71) 71
oncology (71) 71
psma (67) 67
prostatic neoplasms - pathology (66) 66
glutamate carboxypeptidase ii (64) 64
pharmacology & pharmacy (63) 63
membrane antigen (62) 62
prostatic neoplasms - drug therapy (61) 61
prostatic neoplasms - therapy (61) 61
prostatic neoplasms - metabolism (56) 56
antigens, surface - immunology (54) 54
glutamate carboxypeptidase ii - immunology (53) 53
prostate-specific membrane antigen (50) 50
middle aged (49) 49
article (47) 47
prostatic neoplasms - immunology (47) 47
aged (46) 46
therapy (46) 46
neurosciences (45) 45
antigens, surface (42) 42
glutamate carboxypeptidase ii - genetics (42) 42
antigens (39) 39
antigens, surface - genetics (39) 39
female (39) 39
rats (39) 39
research (39) 39
urologic and male genital diseases (39) 39
prostatic neoplasms - diagnostic imaging (38) 38
health aspects (37) 37
urology & nephrology (37) 37
tumors (36) 36
amino acids (35) 35
care and treatment (35) 35
ligands (35) 35
prostate (35) 35
biochemistry & molecular biology (34) 34
medicine (33) 33
treatment outcome (31) 31
immunotherapy (30) 30
medicine, research & experimental (30) 30
prostatic neoplasms - diagnosis (30) 30
n-acetylaspartylglutamate (29) 29
disease models, animal (28) 28
mice, nude (28) 28
physiological aspects (27) 27
antibodies, monoclonal - therapeutic use (26) 26
glutamate-carboxypeptidase-ii (26) 26
neoplasm metastasis (25) 25
radiology, nuclear medicine & medical imaging (25) 25
analysis (24) 24
extracellular domain (24) 24
glutamate carboxypeptidase-ii (24) 24
membrane antigen psma (24) 24
monoclonal-antibody (24) 24
patents (24) 24
psychiatry (24) 24
aged, 80 and over (23) 23
chemistry, medicinal (23) 23
enzyme inhibitors - pharmacology (23) 23
immunohistochemistry (23) 23
in-vivo (23) 23
research article (23) 23
brain (22) 22
carcinoma (22) 22
diagnosis (22) 22
endocrinology & metabolism (22) 22
enzymes (22) 22
linked acidic dipeptidase (22) 22
multidisciplinary sciences (22) 22
nervous system (22) 22
prostatic neoplasms - genetics (22) 22
urea-based inhibitors (22) 22
drug delivery systems (21) 21
metastasis (21) 21
positron-emission-tomography (21) 21
tumor cells, cultured (21) 21
prostate-specific antigen (20) 20
prostatic neoplasms - radiotherapy (20) 20
rats, sprague-dawley (20) 20
tumor-associated neovasculature (20) 20
biotechnology & applied microbiology (19) 19
cells (19) 19
glutamate carboxypeptidase ii - chemistry (19) 19
radical prostatectomy (19) 19
antineoplastic agents - therapeutic use (18) 18
glutamate carboxypeptidase ii - analysis (18) 18
inhibitors (18) 18
monoclonal-antibodies (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PloS one, ISSN 1932-6203, 2016, Volume 11, Issue 9, p. e0162303
Journal Article
Journal Article
Cancer Biotherapy and Radiopharmaceuticals, ISSN 1084-9785, 09/2018, Volume 33, Issue 7, pp. 274 - 281
Background: Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding field in the management of... 
bone metastases | lutetium | response to treatment | prostate cancer | metastasis | bone marrow | MEDICINE, RESEARCH & EXPERIMENTAL | PRACTICE GUIDELINE | PSMA LIGANDS | CLINICAL-ONCOLOGY | RADIOIMMUNOTHERAPY | PHASE-II | MONOCLONAL-ANTIBODY | WORKING GROUP | ONCOLOGY | RADIOLIGAND THERAPY | PET/CT | PHARMACOLOGY & PHARMACY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | AMERICAN-SOCIETY | Salvage Therapy - adverse effects | Antigens, Surface - therapeutic use | Humans | Middle Aged | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Aged, 80 and over | Radioimmunotherapy - methods | Kallikreins - blood | Retrospective Studies | Lutetium - therapeutic use | Glutamate Carboxypeptidase II - chemistry | Glutamate Carboxypeptidase II - therapeutic use | Glutamate Carboxypeptidase II - immunology | Radioisotopes - therapeutic use | Radiopharmaceuticals - chemistry | Prostatic Neoplasms, Castration-Resistant - blood | Prostatic Neoplasms, Castration-Resistant - radiotherapy | Treatment Outcome | Antigens, Surface - chemistry | Prostate-Specific Antigen - blood | Aged | Neoplasm Staging | Antigens, Surface - immunology | Prostate | Radioimmunotherapy - adverse effects | Radiopharmaceuticals - therapeutic use | Salvage Therapy - methods | Therapy | Nuclear medicine | Laboratories | Toxicity | Leukemia | Liver | Systematic review | Myelodysplasia | Metastasis | Cancer therapies | Metastases | Salvage | Lutetium isotopes | Bone marrow | Tomography | Antigens | Medical imaging | Hematology | Mortality | Patients | Lutetium | Androgens | Medical prognosis | Ligands | Prostate cancer | Cancer | Index Medicus
Journal Article
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 11/2012, Volume 61, Issue 11, pp. 2161 - 2170
Journal Article
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2003, Volume 30, Issue 5, pp. 659 - 666
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e102936
Pyridoxine is used as a supplement for treating conditions such as vitamin deficiency as well as neurological disorders such as depression, epilepsy and... 
PAIN MODEL | PERIPHERAL NERVOUS-SYSTEM | MULTIDISCIPLINARY SCIENCES | NEURONS | ISCHEMIC BRAIN-INJURY | GROWTH-FACTOR | SENSORY NEUROPATHY | DIABETIC-NEUROPATHY | NAALADASE INHIBITION | N-ACETYLASPARTYLGLUTAMATE NAAG | THIOL-BASED INHIBITORS | Neuroprotective Agents - therapeutic use | Peripheral Nervous System Diseases - chemically induced | Glutamate Carboxypeptidase II - antagonists & inhibitors | Sulfhydryl Compounds - pharmacology | Neurodegenerative Diseases - prevention & control | Motor Activity - drug effects | Rats | Peripheral Nervous System Diseases - physiopathology | Rats, Sprague-Dawley | Protease Inhibitors - pharmacology | Sensation - drug effects | Glutarates - therapeutic use | Pyridoxine - adverse effects | Animals | Neurodegenerative Diseases - chemically induced | Neuroprotective Agents - pharmacology | Behavior, Animal - drug effects | Female | Sulfhydryl Compounds - therapeutic use | Glutarates - pharmacology | Protease Inhibitors - therapeutic use | Peripheral Nervous System Diseases - drug therapy | Amino acids | Chemotherapy | Glutamate | Cancer | Conduction | Spinal cord | Neurosciences | Epilepsy | Body weight | Nervous system | Diabetic neuropathy | Carboxypeptidase | Parameter sensitivity | Mental depression | Peripheral neuropathy | Nerve conduction | Neurotoxicity | Lumbar region | Pain | Dorsal root ganglia | Neurodegeneration | Rodents | Sensory neurons | Inhibition | Glutamate carboxypeptidase | Growth factors | Drug dosages | EMG | Nutrient deficiency | Diabetes mellitus | Vitamin deficiency | Pyridoxine | Bioavailability | Reaction time task | Ganglia | Latency | Neurological diseases | Medicine | Autism | Reaction time | Diabetes
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 12/2012, Volume 343, Issue 3, pp. 746 - 754
Peripheral neuropathy from nerve trauma is a significant problem in the human population and often constitutes a dose-limiting toxicity in patients receiving... 
NAAG PEPTIDASE INHIBITORS | ACETYL-ASPARTYL-GLUTAMATE | PHARMACOLOGY & PHARMACY | INFLAMMATORY PAIN | AMYOTROPHIC-LATERAL-SCLEROSIS | DIABETIC-NEUROPATHY | LINKED ACIDIC DIPEPTIDASE | N-ACETYLASPARTYLGLUTAMATE | NAALADASE INHIBITION | THIOL-BASED INHIBITORS | TEMPORAL-LOBE | Sulfhydryl Compounds - administration & dosage | Benzoates - therapeutic use | Glutamate Carboxypeptidase II - antagonists & inhibitors | Benzoates - chemistry | Male | Antineoplastic Agents - therapeutic use | Organoplatinum Compounds - pharmacology | Dose-Response Relationship, Drug | Enzyme Inhibitors - administration & dosage | Tissue Distribution | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Enzyme Inhibitors - chemistry | Female | Mice, Inbred DBA | Sulfhydryl Compounds - chemistry | Antineoplastic Agents - pharmacology | Molecular Structure | Neural Conduction - drug effects | Neuralgia - physiopathology | Sciatic Neuropathy - drug therapy | Disease Models, Animal | Cell Survival - drug effects | Leukemia L1210 - drug therapy | Administration, Oral | Rats | Neuralgia - enzymology | Enzyme Inhibitors - therapeutic use | Rats, Sprague-Dawley | Sciatic Neuropathy - enzymology | Sulfhydryl Compounds - pharmacokinetics | Neuralgia - drug therapy | Benzoates - administration & dosage | Hyperalgesia - physiopathology | Animals | Hyperalgesia - drug therapy | Cell Line, Tumor | Sciatic Neuropathy - physiopathology | Mice | Mice, Inbred BALB C | Sulfhydryl Compounds - therapeutic use | Hyperalgesia - enzymology | Organoplatinum Compounds - therapeutic use | Benzoates - pharmacokinetics | Index Medicus
Journal Article